Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference
Innoviva (NASDAQ: INVA), a diversified holding company, has announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, FL. CEO Pavel Raifeld will engage in a fireside chat on Tuesday, March 11, 2025, at 8:30 a.m. Eastern Time.
The company, which maintains a core royalties portfolio and operates the Innoviva Specialty Therapeutics (IST) platform focusing on critical care and infectious diseases, will provide a live webcast of the presentation. Investors can access the webcast through the Investor Relations section of Innoviva's website under 'Events & Presentations' at investor.inva.com/presentations-events. The presentation recording will remain available for replay for 90 days after the event.
Innoviva (NASDAQ: INVA), una società di holding diversificata, ha annunciato la sua partecipazione alla 27ª Conferenza Annuale Globale sulla Salute di Barclays a Miami, FL. Il CEO Pavel Raifeld parteciperà a una chiacchierata informale martedì 11 marzo 2025, alle 8:30 ora orientale.
L'azienda, che mantiene un portafoglio centrale di royalties e gestisce la piattaforma Innoviva Specialty Therapeutics (IST) focalizzata sulla terapia intensiva e sulle malattie infettive, offrirà una diretta web della presentazione. Gli investitori possono accedere alla diretta attraverso la sezione Relazioni con gli Investitori del sito web di Innoviva sotto 'Eventi e Presentazioni' all'indirizzo investor.inva.com/presentations-events. La registrazione della presentazione rimarrà disponibile per la riproduzione per 90 giorni dopo l'evento.
Innoviva (NASDAQ: INVA), una empresa de holding diversificada, ha anunciado su participación en la 27ª Conferencia Anual Global de Salud de Barclays en Miami, FL. El CEO Pavel Raifeld participará en una charla informal el martes 11 de marzo de 2025, a las 8:30 a.m. hora del Este.
La compañía, que mantiene una cartera central de regalías y opera la plataforma Innoviva Specialty Therapeutics (IST) centrada en cuidados críticos y enfermedades infecciosas, ofrecerá una transmisión en vivo de la presentación. Los inversores pueden acceder a la transmisión a través de la sección de Relaciones con Inversores del sitio web de Innoviva bajo 'Eventos y Presentaciones' en investor.inva.com/presentations-events. La grabación de la presentación estará disponible para su reproducción durante 90 días después del evento.
Innoviva (NASDAQ: INVA)는 다각화된 지주회사로서 바클레이스 제27회 연례 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO 파벨 라이펠드는 2025년 3월 11일 화요일 오전 8시 30분 동부 표준시에 화상 대화에 참여할 예정입니다.
이 회사는 핵심 로열티 포트폴리오를 유지하고 중환자 치료 및 감염병에 중점을 둔 Innoviva Specialty Therapeutics (IST) 플랫폼을 운영하며, 발표의 라이브 웹캐스트를 제공합니다. 투자자들은 Innoviva 웹사이트의 '투자자 관계' 섹션에서 '이벤트 및 발표'를 통해 웹캐스트에 접근할 수 있습니다. 발표 녹화는 이벤트 후 90일 동안 재생할 수 있습니다.
Innoviva (NASDAQ: INVA), une société holding diversifiée, a annoncé sa participation à la 27ème Conférence Annuelle Mondiale sur la Santé de Barclays à Miami, FL. Le PDG Pavel Raifeld participera à une discussion informelle le mardi 11 mars 2025, à 8h30 heure de l'Est.
L'entreprise, qui maintient un portefeuille central de redevances et gère la plateforme Innoviva Specialty Therapeutics (IST) axée sur les soins critiques et les maladies infectieuses, proposera une diffusion en direct de la présentation. Les investisseurs peuvent accéder à la diffusion via la section Relations Investisseurs du site web d'Innoviva sous 'Événements et Présentations' à l'adresse investor.inva.com/presentations-events. L'enregistrement de la présentation sera disponible en replay pendant 90 jours après l'événement.
Innoviva (NASDAQ: INVA), ein diversifiziertes Holdingunternehmen, hat seine Teilnahme an der 27. jährlichen globalen Gesundheitskonferenz von Barclays in Miami, FL, bekannt gegeben. CEO Pavel Raifeld wird am Dienstag, den 11. März 2025, um 8:30 Uhr Eastern Time an einem informellen Gespräch teilnehmen.
Das Unternehmen, das ein zentrales Portfolio an Lizenzgebühren pflegt und die Plattform Innoviva Specialty Therapeutics (IST) betreibt, die sich auf Intensivpflege und Infektionskrankheiten konzentriert, wird eine Live-Übertragung der Präsentation anbieten. Investoren können über den Bereich Investor Relations auf der Website von Innoviva unter 'Events & Presentations' auf die Übertragung zugreifen: investor.inva.com/presentations-events. Die Aufzeichnung der Präsentation bleibt 90 Tage nach der Veranstaltung für eine Wiederholung verfügbar.
- None.
- None.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250305429112/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
FAQ
When is Innoviva (INVA) presenting at the Barclays Healthcare Conference 2025?
How can investors watch Innoviva's (INVA) presentation at the Barclays Conference?
How long will Innoviva's (INVA) Barclays Conference presentation be available for replay?
What are the main business segments of Innoviva (INVA) as presented at the Barclays Conference?
